Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients.
Transplantation proceedings, cilt.51, sa.4, ss.1118-1120, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 4
- Basım Tarihi: 2019
- Doi Numarası: 10.1016/j.transproceed.2019.01.106
- Dergi Adı: Transplantation proceedings
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1118-1120
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İstanbul Üniversitesi Adresli: Evet
Özet
Introduction. Cardiovascular disease is the leading cause of mortality in kidney transplant recipients. Rituximab is widely used in kidney transplantation for a variety of situations, and rituximab may inhibit some cytokines and antibodies that may play an active role in the atherosclerotic process. The aim of the study was to evaluate the efficacy of rituximab on atherosclerosis biomarkers in kidney transplant recipients.